Shares of Axovant Gene Therapies Ltd (NASDAQ:AXGT) have been assigned an average rating of “Buy” from the eleven ratings firms that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $29.83.

Several research firms have recently commented on AXGT. Leerink Swann began coverage on Axovant Gene Therapies in a report on Friday, June 21st. They issued an “outperform” rating and a $5.79 price target for the company. Robert W. Baird raised Axovant Gene Therapies from a “neutral” rating to an “outperform” rating and reduced their price target for the company from $16.00 to $13.00 in a report on Monday, August 12th. Zacks Investment Research cut Axovant Gene Therapies from a “buy” rating to a “hold” rating in a report on Wednesday, August 14th. Svb Leerink initiated coverage on Axovant Gene Therapies in a report on Friday, June 21st. They issued an “outperform” rating and a $18.00 price target for the company. Finally, Cowen reaffirmed a “hold” rating on shares of Axovant Gene Therapies in a report on Tuesday, July 9th.

Shares of AXGT traded down $0.05 during mid-day trading on Friday, hitting $7.57. The company’s stock had a trading volume of 23,197 shares, compared to its average volume of 100,518. The company has a current ratio of 1.70, a quick ratio of 1.70 and a debt-to-equity ratio of 0.60. The firm has a 50-day simple moving average of $6.74 and a 200 day simple moving average of $4.71. The firm has a market capitalization of $172.67 million, a P/E ratio of -0.94 and a beta of 1.26. Axovant Gene Therapies has a 1-year low of $3.81 and a 1-year high of $20.80.

Axovant Gene Therapies (NASDAQ:AXGT) last posted its quarterly earnings results on Friday, August 9th. The company reported ($1.23) EPS for the quarter, beating the consensus estimate of ($1.34) by $0.11. As a group, sell-side analysts predict that Axovant Gene Therapies will post -4.25 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AXGT. Sphera Funds Management LTD. acquired a new position in shares of Axovant Gene Therapies in the first quarter worth $6,794,000. Primecap Management Co. CA acquired a new position in shares of Axovant Gene Therapies in the first quarter worth $1,400,000. BlackRock Inc. acquired a new position in shares of Axovant Gene Therapies in the second quarter worth $1,482,000. Marshall Wace LLP purchased a new stake in shares of Axovant Gene Therapies in the first quarter valued at $272,000. Finally, Jane Street Group LLC grew its position in shares of Axovant Gene Therapies by 28.8% in the second quarter. Jane Street Group LLC now owns 46,455 shares of the company’s stock valued at $289,000 after purchasing an additional 10,375 shares during the period. 13.48% of the stock is owned by institutional investors.

Axovant Gene Therapies Company Profile

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Featured Article: Margin

Analyst Recommendations for Axovant Gene Therapies (NASDAQ:AXGT)

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.